Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery

Drug delivery is one of the most dynamic and fast growing sectors of the pharmaceutical industry. The high level of innovation in this sector is evolving at a fast pace with products such as Pfizer’s inhaled insulin, Exubera, gaining US approval in January 2006.

‘Innovation in Drug Delivery’ provides an in-depth examination of product launches and pipeline drugs with novel drug delivery mechanisms set to revolutionize the market, such as products using ALZA Corporation’s E-TRANS and Altea’s PassPort patch transdermal technologies. This report will enable you to evaluate key marketed drugs, including Emend and Megace, and gain an insight into novel pipeline products to anticipate upcoming product launches and position yourself for success.

Use this report to understand how nanotechnology and other key technologies are changing drug delivery and how these can be implemented into your R&D process. Assess the impact of innovation in therapy areas including oncology, diabetes and infectious diseases and identify future opportunities for market growth.

Some key findings from this report...

Solubility is a key resistor to drug delivery and a major factor causing attrition and poor efficacy in drug development, with an estimated 30% of drugs in pre-clinical development having low solubility.

Abraxane and Doxil are both innovative marketed oncology products utilizing nanotechnology, gaining sales of $184m and $177m in the US and 5 major European countries in 2005, respectively.

There are several high potential inhaled monoclonal antibodies in development, including products from Enzon and Nektar, Alexion and Medimmune, and Alkermes.

Active transdermal patches are predominantly indicated for pain and women’s health, but products using ALZA’s E-TRANS and Altea’s PassPort patch technology are predicted to available for protein delivery within the next few years, and consequently will increase the range of accessible indications for transdermal delivery.

Drug eluting stents are typically 3 to 4 fold more expensive than bare metal stents and have elicited safety concerns, however next generation drug-eluting stents consist of bio-absorbable polymers and are predicted to be safer.

Key questions answered in this report

What are the key drivers of innovation in drug delivery and how are they impacting the pharmaceutical market?

How is nanotechnology driving forward innovation and what is its impact on each therapy area?

What strategies are the leading drug delivery companies implementing to maximize sales and boost market share?

Who are the leading innovators in transdermal and pulmonary drug delivery?

Which new product launches will gain high sales and challenge the current market leaders?

What are the key trends in drug delivery and how will they impact future sales?

Which innovative drug delivery technologies have the highest future potential?

Top five reasons to order your copy today

Understand how nanotechnology is revolutionizing drug delivery and how this can be implemented into your own R&D process.

Evaluate key marketed drugs with innovative drug delivery and gain insight into novel pipeline products to identify your competitive position and anticipate upcoming product launches.

Gain access to the latest information on key technologies in drug delivery, with the report’s comprehensive coverage of leaders in each field.

Assess the impact of innovation in drug delivery in therapy areas including oncology, diabetes and infectious diseases and identify future opportunities for market growth.

Implement strategies to address the key unmet needs in drug delivery and current and future challenges in key indications, enabling you to plan for future success.

Publication Date: Nov-06

Pages: 137

Format: PDF
Table of Contents
Price: $2,875.00 / GBP1,897.50